JP2016507546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507546A5 JP2016507546A5 JP2015556537A JP2015556537A JP2016507546A5 JP 2016507546 A5 JP2016507546 A5 JP 2016507546A5 JP 2015556537 A JP2015556537 A JP 2015556537A JP 2015556537 A JP2015556537 A JP 2015556537A JP 2016507546 A5 JP2016507546 A5 JP 2016507546A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dose
- aminosulfonyl
- thiazol
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012458 free base Substances 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000002253 acid Substances 0.000 claims 20
- IVZKZONQVYTCKC-UHFFFAOYSA-N bay 57-1293 Chemical compound N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 IVZKZONQVYTCKC-UHFFFAOYSA-N 0.000 claims 20
- 150000004682 monohydrates Chemical class 0.000 claims 19
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 208000037952 HSV-1 infection Diseases 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 229940121759 Helicase inhibitor Drugs 0.000 claims 3
- 108060004795 Methyltransferase Proteins 0.000 claims 3
- 229940122488 Primase inhibitor Drugs 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 claims 2
- 102100022033 Presenilin-1 Human genes 0.000 claims 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- -1 2-pyridinyl Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 101150037123 APOE gene Proteins 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 claims 1
- 102100029470 Apolipoprotein E Human genes 0.000 claims 1
- 101710095339 Apolipoprotein E Proteins 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000003205 genotyping method Methods 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13154982 | 2013-02-12 | ||
| EP13154982.6 | 2013-02-12 | ||
| PCT/EP2014/052743 WO2014124978A2 (en) | 2013-02-12 | 2014-02-12 | Helicase-primase inhibitors for use in a method of treating alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016507546A JP2016507546A (ja) | 2016-03-10 |
| JP2016507546A5 true JP2016507546A5 (enExample) | 2016-04-21 |
Family
ID=47709982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556537A Withdrawn JP2016507546A (ja) | 2013-02-12 | 2014-02-12 | アルツハイマー病を治療する方法において使用するためのヘリカーゼ／プライマーゼ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150374676A1 (enExample) |
| EP (1) | EP2956134A2 (enExample) |
| JP (1) | JP2016507546A (enExample) |
| KR (1) | KR20150119089A (enExample) |
| CN (1) | CN105101963A (enExample) |
| AU (1) | AU2014217962A1 (enExample) |
| BR (1) | BR112015019220A2 (enExample) |
| CA (1) | CA2898798A1 (enExample) |
| CL (1) | CL2015002241A1 (enExample) |
| EA (1) | EA201500836A1 (enExample) |
| IL (1) | IL240459A0 (enExample) |
| MX (1) | MX2015010339A (enExample) |
| PH (1) | PH12015501762A1 (enExample) |
| SG (1) | SG11201506153TA (enExample) |
| WO (1) | WO2014124978A2 (enExample) |
| ZA (1) | ZA201505243B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| WO2018096177A1 (en) * | 2016-11-28 | 2018-05-31 | Aicuris Anti-Infective Cures Gmbh | A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses |
| US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
| TW202038947A (zh) * | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| WO2022108381A1 (ko) | 2020-11-19 | 2022-05-27 | 주식회사 오에이티씨 | 디다노신을 포함하는 신경염증성 질환 예방 또는 치료용 조성물 |
| JP2025530762A (ja) * | 2022-08-29 | 2025-09-17 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | ヘルペスウイルス用医薬組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| US8299059B2 (en) * | 2009-10-30 | 2012-10-30 | Eli Lilly And Company | Crystalline compound and a process for its preparation |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
-
2014
- 2014-02-12 EP EP14703891.3A patent/EP2956134A2/en not_active Withdrawn
- 2014-02-12 SG SG11201506153TA patent/SG11201506153TA/en unknown
- 2014-02-12 CN CN201480008550.6A patent/CN105101963A/zh active Pending
- 2014-02-12 BR BR112015019220A patent/BR112015019220A2/pt not_active IP Right Cessation
- 2014-02-12 AU AU2014217962A patent/AU2014217962A1/en not_active Abandoned
- 2014-02-12 US US14/767,163 patent/US20150374676A1/en not_active Abandoned
- 2014-02-12 MX MX2015010339A patent/MX2015010339A/es unknown
- 2014-02-12 KR KR1020157024625A patent/KR20150119089A/ko not_active Withdrawn
- 2014-02-12 WO PCT/EP2014/052743 patent/WO2014124978A2/en not_active Ceased
- 2014-02-12 EA EA201500836A patent/EA201500836A1/ru unknown
- 2014-02-12 CA CA2898798A patent/CA2898798A1/en not_active Abandoned
- 2014-02-12 JP JP2015556537A patent/JP2016507546A/ja not_active Withdrawn
-
2015
- 2015-07-21 ZA ZA2015/05243A patent/ZA201505243B/en unknown
- 2015-08-09 IL IL240459A patent/IL240459A0/en unknown
- 2015-08-11 PH PH12015501762A patent/PH12015501762A1/en unknown
- 2015-08-11 CL CL2015002241A patent/CL2015002241A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016507546A5 (enExample) | ||
| CN103402519B (zh) | 肿瘤治疗剂 | |
| JP2016512531A5 (enExample) | ||
| CN109328187A (zh) | 一种具有fgfr抑制活性的新型化合物及其制备和应用 | |
| JP2017533922A5 (enExample) | ||
| JP2019526596A5 (enExample) | ||
| TW202019891A (zh) | 胺烷基苯並硫氮呯衍生物之用途 | |
| CN106999462A (zh) | 包含选择性s1p1受体激动剂的药物组合物 | |
| JP2019501879A5 (enExample) | ||
| BR112019014924A2 (pt) | Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1 | |
| JP2018509474A (ja) | インダン酢酸誘導体を用いる肝疾患の治療方法 | |
| KR20200131816A (ko) | 캡시드 조립 조절제 투약 요법 | |
| WO2022140410A1 (en) | Methods of treating cancer | |
| WO2014124978A4 (en) | Helicase-primase inhibitors for use in a method of treating alzheimer's disease | |
| US20230115867A1 (en) | Pemafibrate Dosing Regimens | |
| CN102665716B (zh) | 用于治疗唐氏综合征的方法和药物组合物 | |
| TW201323425A (zh) | 抗菌性咔啉化合物 | |
| KR102220260B1 (ko) | 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘 | |
| JPWO2002072097A1 (ja) | 糖尿病由来虚血性心疾患の治療及び／または予防剤 | |
| JP6279465B2 (ja) | 治療計画 | |
| US20230210825A1 (en) | Methods and compositions for treating subjects with metabolic disorders and coronavirus infections | |
| JP7658909B2 (ja) | 筋ジストロフィー治療薬 | |
| JP2020050624A (ja) | 線維症治療用医薬組成物 | |
| ES2741434T3 (es) | Piridilhidrazonas para el tratamiento de tuberculosis y enfermedades relacionadas | |
| JP5794873B2 (ja) | 抗腫瘍剤 |